Acelrx Pharmaceuticals Inc., of Redwood City, Calif., said it entered an agreement with funds affiliated with Armistice Capital and Rock Springs Capital for the sale of 9.43 million shares priced at $1.06 each for gross proceeds of approximately $10 million.
Allovir Inc., of Cambridge, Mass., which recently filed with the SEC for an IPO of up to $100 million, has set terms for its offering and now plans to raise up to $251 million from the sale of 14.8 million shares at a price range of $16 to $18. It has in the works phase II and III trials of lead candidate Viralym-M, a multivirus-specific T-cell therapy targeting five viruses. The company is focusing initially on treating immunocompromised allogeneic hematopoietic stem cell transplant and solid organ transplant patients at high risk for life-threatening viral infections from the viruses targeted by Viralym-M. The Baylor College of Medicine spin-out previously reported positive data from a completed phase II trial. The proceeds also will fund planned trials of pipeline candidates ALVR-106, a virus-specific T-cell therapy targeting respiratory viruses, and allogeneic virus-targeted cell therapies ALVR-107 in chronic human hepatitis B virus, ALVR-108 in human herpes virus 8-associated diseases and ALVR-109 in COVID-19 infection. Allovir plans to list on Nasdaq under the symbol ALVR.
Annexon Inc., of South San Francisco, has increased the terms for its IPO and now plans to offer 12.5 million shares priced between $15 and $16 each. The financing is intended to support development for multiple product candidates in the company’s portfolio, including ANX-005, an investigational monoclonal antibody designed to block C1q and activation of the classical complement cascade, that is advancing into a phase II/III trial in patients with Guillain-Barré syndrome, with additional plans to advance into warm autoimmune hemolytic anemia, Huntington’s disease and amyotrophic lateral sclerosis. Funds will also support ANX-007, a C1q antigen-binding fragment, or Fab, designed for intravitreal administration in patients with complement-mediated neurodegenerative ophthalmic disorders, that is advancing into a phase II trial in geographic atrophy. The company plans to list on Nasdaq under the symbol ANNX.
Arthex Biotech SL, of Valencia, Spain, which is focused on the development of next-generation antisense RNA therapies for the treatment of myotonic dystrophy type 1 (DM1), said it closed a funding round of €4.25 million (US$4.9 million). The new funding, provided by Advent France Biotechnology (AFB) and Invivo Ventures, will support advancing its therapy to a first-in-human trial by 2022.
Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, said it priced an underwritten public offering of 13.33 million common shares at $15 each for gross proceeds of approximately $200 million. The underwriters have received an option to purchase up to 2 million shares. The company intends to use the net proceeds of the offering for pre-commercialization and launch activities, research and development, as well as working capital and general corporate purposes.
Biontech SE, of Mainz, Germany, said it priced its underwritten offering of 5.5 million American depositary shares (ADSs), each representing one of its ordinary shares, at $93 per ADS, for gross proceeds of $511.5 million. The size of the offering was increased from the previously announced offering size of 5 million ADSs. The company also announced the terms of a rights offering to subscribe for up to 7.5 million ordinary shares, including ordinary shares represented by ADSs, extended to holders of its ordinary shares and ADSs.
Inozyme Pharma Inc., of Cambridge, Mass., has increased the terms for its IPO and now plans to raise $104 million by offering 6.5 million shares at $16 each. Its lead product candidate, INZ-701, is a soluble, recombinant fusion protein that is designed to correct a defect in the mineralization pathway caused by the enzyme ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and ABCC6 deficiencies. The company plans to file an IND with the FDA and clinical trial authorizations with regulatory authorities in Europe for INZ-701 later this year. Shares are expected to trade on Nasdaq under the symbol INZY.
Longwood Fund, of Boston, said it closed its fifth fund with approximately $170 million in total capital commitments. The fund focuses on creating new companies, as well as investing in the first institutional rounds of established companies, that have platforms to deliver therapeutics and medical solutions that advance science and transform health care.
Milestone Pharmaceuticals Inc., of Montreal, signed a securities purchase agreement with affiliates of an existing shareholder, RTW Investments LP, for a $25 million private placement. The deal is expected to close on or about July 24. Specifically, the firm is selling prefunded warrants to acquire about 6.6 million common shares at a price of about $3.74 each. Milestone believes that net proceeds from the private placement, together with its existing cash, cash equivalents and short-term investments, will be sufficient to fund its planned operations into the second quarter of 2022.
Nervgen Pharma Corp., of Vancouver, British Columbia, disclosed a “best efforts” public offering of equity securities. The offering will be led by Haywood Securities Inc. as sole bookrunner and lead agent, on behalf of a syndicate of agents. It will take place in each of the provinces of British Columbia, Alberta, Ontario and Nova Scotia, Nervgen said.
Nurix Therapeutics Inc., of San Francisco, hiked the terms for its IPO. The company intends to raise $193 million by offering 11 million shares at a price range of $17 to $18. Previous terms involved 8.8 million shares at a range of $16 to $18. The company plans to list on Nasdaq under the symbol NRIX. J.P. Morgan, Piper Sandler and Stifel are the joint bookrunners.
Scopus Biopharma Inc., of New York, filed to raise up to $6 million in an IPO by offering 1 million shares at a price range of $5.25 to $5.75. With an immune-oncology gene therapy in the works, Scopus plans to list on Nasdaq under the symbol SCPS. The Benchmark Co. is the sole bookrunner on the deal.